

**SPA 25-0014 Estimated Cost Related to Coverage of Oral Weight Loss Medications**

	SFY 2025	SFY 2026	SFY 2027
<b>Gross Cost</b>	\$ 504,008	\$ 4,412,069	\$ 3,274,037
<b>Federal Share</b>	\$ 313,422	\$ 2,743,683	\$ 2,035,988
<b>State Share</b>	\$ 190,586	\$ 1,668,386	\$ 1,238,049

  

	FFY 2025	FFY 2026	FFY 2027
<b>Gross Cost</b>	\$ 2,016,032	\$ 3,695,194	\$ 3,297,892
<b>Federal Share</b>	\$ 1,253,687	\$ 2,297,888	\$ 2,050,823
<b>State Share</b>	\$ 762,345	\$ 1,397,306	\$ 1,247,069

This proposed change is estimated to have a gross fiscal impact of \$504,008 in SFY 2025, \$4,412,069 in SFY 2026, and \$3,274,037 in SFY 2027.

**Assumptions**

- Proposed medications to be added are Phentermine, Xenical and Orlistat.
- Estimated costs are net of rebates.
- Weighted average cost per drug based on ratios found in denied claims data from SFY24.
- Estimated number of recipients is derived from claims with an obesity diagnosis and with dates of service in CY 2023. The estimated number of members with Type 2 diabetes were excluded because they are assumed to be prescribed GLP-1s rather than the proposed oral medications.
- Pool of qualifying members is based on CT legislation covering weight loss drugs for those with a BMI of 35+.
- Effective date June 1, 2025.
- Federal share of 62.2% is based on eligibility found in denied claims data.

Date of

request: January 15, 2025

Requestor: Herman Kranc

Analyst: Margaret O'Keefe